Drug Profile
Research programme: E2F-targeting anticancer therapeutics - TopoTarget
Alternative Names: E2F research programme - TopoTarget; E2F-targeting anticancer therapeutics research programme - TopoTargetLatest Information Update: 10 Jul 2009
Price :
$50
*
At a glance
- Originator TopoTarget
- Class Small molecules
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Jul 2009 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
- 10 Jul 2009 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 23 Jan 2004 This programme is available for licensing (http://www.topotarget.com)